Fosgonimeton is under clinical development by Athira Pharma and currently in Phase II for Lewy Body Dementia. According to GlobalData, Phase II drugs for Lewy Body Dementia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Fosgonimeton LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fosgonimeton is under development for the treatment of Alzheimer’s disease, diabetic neuropathy, Parkinson's disease dementia and dementia with lewy bodies. It is administered subcutaneously. The drug candidate acts by targeting hepatocyte growth factor and its receptor (MET).
Athira Pharma overview
Athira Pharma, is a biopharmaceutical company that develops small molecules to treat neurodegenerative diseases and restore neuronal health. It is investigating ATH-1017, a small molecule drug for the treatment of Alzheimer’s and Parkinson’s disease; ATH-1020 against neuropsychiatric disorders; and Early Compounds that is Neuropathic Pain. The company works in partnership with contract development and manufacturing organizations to manufacture and supply preclinical and clinical materials for development of product candidates. Athira Pharma is headquartered in Bothell, Washington, the US.
For a complete picture of Fosgonimeton’s drug-specific PTSR and LoA scores, buy the report here.